PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025" report to their offering.

Schizophrenia treatment urgently requires drugs targeting negative symptoms.

The schizophrenia market across the seven major markets of the US, France, Germany, Italy, Spain, the UK, and Japan, is set to rise from $6.4 billion in 2015 to $7.3 billion by 2025, registering a compound annual growth rate of 1.4%.

The report states that major drivers of this modest growth include the uptake of novel pipeline products that have been designed to satisfy unmet needs in the disease and development of long-acting injectable (LAI) formulations of atypical antipsychotics in order to improve patient compliance, a notable unmet need.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

4 Epidemiology

5 Disease Management

6 Competitive Assessment

7 Unmet Needs and Opportunities

8 Pipeline Assessment

9 Current and Future Players

10 Market Outlook

11 Appendix

Companies Mentioned

  • Alexza Pharmaceuticals
  • Alkermes
  • Allergan
  • Almirall Prodesfarma
  • Astellas
  • AstraZeneca
  • Bristol-Myers Squibb
  • Dainippon Sumitomo/Sunovion
  • Eli Lilly
  • Epomedics
  • Ferrer
  • Gedeon Richter
  • HLS Therapeutics
  • Indivior
  • Intra-Cellular Therapies
  • Janssen
  • Laboratorios Farmaceuticos Rovi
  • Lundbeck
  • Meiji Seika
  • Merck & Co.
  • Minerva Neurosciences
  • Mitsubishi Tanabe Pharma
  • Neurocrine Biosciences
  • Nitto Denko Corporation
  • Novartis
  • Otsuka
  • Pfizer
  • Sandoz
  • Sanofi
  • SyneuRx
  • Takeda
  • Teva Pharmaceutical
  • Titan Pharmaceutical
  • Vanda Pharmaceuticals
  • Yoshitomi Yakuhin Corporation

For more information about this report visit http://www.researchandmarkets.com/research/wwfq9j/pharmapoint

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Schizophrenia Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Schizophrenia Drugs